← Back to 5-MeO-AMT

5-MeO-AMT Stats & Data

Alpha Alpha-o α,o-dms α,o-dimethylserotonin 5meoamt 5-MeO-αMT

PubChem CID 36906

NPS DataHub

MW204.27

FormulaC12H16N2O

CAS1137-04-8

IUPAC1-(5-methoxy-1~{H}-indol-3-yl)propan-2-amine

SMILESCOc1ccc2ncc(CC(C)N)c2c1

InChIKeyOGNJZVNNKBZFRM-QMMMGPOBSA-N

Tryptamines

Chemical Class alpha-Alkyltryptamine

Psychoactive Class Psychedelic / Stimulant

Effect Profile

Curated + 96 Reports

Psychedelic 6.1

Strong visuals and auditory effects with strong body load, low headspace

Visual Intensity×3

10104.1

Headspace Depth×3

34.310

Auditory Effects×1

109.72.5

Body Load / Somatic Effects×1

10108.1

Catalog Erowid BlueLight

Empathogen 9.3

Strong empathy, sensory enhancement, stimulation, and euphoria

Empathy / Social Openness×3

103.02.5

Euphoria / Mood Elevation×2

85.15.4

Stimulation×1

94.210

Sensory Enhancement×1

106.25.0

Catalog Erowid BlueLight

Stimulant 5.0

Strong stimulation with strong anxiety/jitters, moderate euphoria, low focus

Stimulation / Energy×3

85.0

Euphoria / Mood Lift×2

74.3

Focus / Productivity×2

11.1

Anxiety / Jitters×1

1010

Catalog Erowid

Based on reports from:

Bluelight Big & Dandy Thread Erowid Experience Reports

Duration Timeline

Bluelight

Onset Comeup Peak Offset After Effects

Oral

30 minutes - 2.0 hours

1-2 hours

3-8 hours

3-6 hours

4-24 hours

Insufflated

4-19 minutes

19-40 minutes

3-8 hours

3-6 hours

4-24 hours

Rectal

4-19 minutes

30 minutes - 1.0 hours

3-8 hours

3-6 hours

4-24 hours

Empirical Duration

Erowid Reports

Median times after the dose that Erowid reports state. A curve is drawn only when reports state all four points (onset, peak begins, comedown begins, back to baseline) and the medians fall in that order. No point is estimated from another.

Oral (24 reports)

Onset T+2h13 reports Peak begins T+4h5 reports Comedown begins T+8.6h6 reports Back to baseline not stated

No curve: fewer than 5 reports state the return to baseline, and no point is estimated from another.

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Unknown in humans; no robust, peer‑reviewed human pharmacokinetic data are available. Long subjective duration suggests slow clearance and/or active metabolites, but direct half‑life estimates are not established.

Addiction Potential

Low. No clear evidence for physical dependence; psychological habituation is possible. Animal data show hallucinogen-like discriminative stimulus without psychostimulant-like reinforcement, suggesting low abuse liability, but long duration and stimulation can encourage risky redosing in inexperienced users.

Tolerance Decay

Half tolerance 7d Baseline ~10d

Animal data show rapid tolerance to head-twitch with repeated dosing; users commonly report diminished effects for several days after use with partial recovery by ~3 days and near-baseline after ~10–14 days. Cross-tolerance with classic psychedelics is expected given shared 5‑HT2A agonism, but human quantification is lacking.

Cross-Tolerances

LSD

Psilocybin

DMT

Experience Report Analysis

Erowid BlueLight

136 Reports

88 Single-substance

2000–2019 Date Range

12 With Age Data

31 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 96 experience reports (88 single-substance Erowid + 8 Bluelight)

96 Reports

85 Effects Detected

33 Positive

44 Adverse

8 Neutral

Effect Sentiment Distribution

Confidence Distribution

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Rows resting on fewer than 20 reports show a count (“3 of 7”) instead of a bar. Why 20?

Positive Effects 33

Visual Distortions 67.7% 80%

Stimulation 31.3% 81%

Color Enhancement 31.2% 84%

Euphoria 30.2% 86%

Music Enhancement 22.9% 90%

Closed-Eye Visuals 14.8% 70%

Empathy 14.6% 80%

Body High 13.5% 85%

Open-Eye Visuals 10.4% 75%

Tactile Enhancement 10.4% 80%

Focus Enhancement 6.3% 75%

Introspection 5.7% 70%

Brightness Enhancement 3 of 8 87%

Melting/flowing 3 of 8 83%

Thought Acceleration 3 of 8 80%

Surface Breathing 3 of 8 85%

Patterning 3 of 8 83%

Visual Trails 2 of 8 88%

Joy 2 of 8 80%

Geometric Imagery 2 of 8 82%

Adverse Effects 44

Nausea 52.1% 87%

Anxiety 41.7% 78%

Confusion 20.5% 70%

Pupil Dilation 14.6% 83%

Sweating 11.5% 95%

Muscle Tension 10.2% 70%

Headache 9.4% 75%

Memory Suppression 6.8% 70%

Increased Heart Rate 6.8% 70%

Jaw Clenching 6.8% 70%

Motor Impairment 5.2% 80%

⚠ Psychosis 4.5% 70%

⚠ Seizure 4.5% 70%

Body Load 5 of 8 81%

Vomiting 3 of 8 92%

Diarrhea 3 of 8 82%

Insomnia 3 of 8 88%

Dizziness 2 of 8 90%

Depersonalization 2 of 8 82%

Dry Mouth 1 of 8 75%

⚠ Suicidal Ideation 1 of 8 85%

Show 23 more adverse effects

Stomach Cramps 1 of 8 75%

Thought Disorganization 1 of 8 75%

Body Temperature Change 1 of 8 70%

Chills 1 of 8 80%

Focus Suppression 1 of 8 80%

Sociability Suppression 1 of 8 75%

Libido Suppression 1 of 8 85%

Amnesia 1 of 8 95%

Environmental Transfiguration 1 of 8 95%

Entity Imagery 1 of 8 90%

Fear 1 of 8 95%

Panic 1 of 8 95%

Paranoia 1 of 8 85%

Catatonia 1 of 8 75%

Delusion 1 of 8 85%

Existential Insight 1 of 8 65%

Disinhibition 1 of 8 80%

Irritability 1 of 8 80%

Tingling 1 of 8 85%

Temporal Disorientation 1 of 8 75%

Dysphoria 1 of 8 90%

Sadness 1 of 8 85%

Pain Enhancement 1 of 8 85%

Show 8 neutral or unclassified mentions

Sedation 22.7%

Hospital 21.6%

Auditory Effects 19.8%

Ego Dissolution 11.4%

Dissociation 6.8%

Time Distortion 3.4%

Time Dilation 5 of 8

Numbness 2 of 8

Also reported in combinations. In the 48 5-MeO-AMT reports where another drug was taken too, 6 (12.5%) mention hospital, emergency services or an overdose, 0 (0.0%) a seizure and 1 (2.1%) psychosis. In the 88 single-substance reports: 21.6%, 4.5% and 4.5%. These are not in the figures above: they cannot be put down to 5-MeO-AMT alone, and a mention is not always something that happened to the writer.

Dose-Response Correlation

How effect frequency changes across dose levels. Whiskers, and the numbers' hover text, give each figure's 95% interval.

View data table

Effect	Heavy (n=27)
Visual Distortions	88.9% (95% interval 72 to 96 percent)
Nausea	74.1% (95% interval 55 to 87 percent)
Anxiety	63.0% (95% interval 44 to 78 percent)
Color Enhancement	48.1% (95% interval 31 to 66 percent)
Stimulation	40.7% (95% interval 24 to 59 percent)
Confusion	37.0% (95% interval 22 to 56 percent)
Auditory Effects	37.0% (95% interval 22 to 56 percent)
Music Enhancement	29.6% (95% interval 16 to 48 percent)
Sedation	25.9% (95% interval 13 to 45 percent)
Empathy	22.2% (95% interval 11 to 41 percent)
Euphoria	22.2% (95% interval 11 to 41 percent)
Pupil Dilation	18.5% (95% interval 8 to 37 percent)
Hospital	18.5% (95% interval 8 to 37 percent)
Closed-Eye Visuals	14.8% (95% interval 6 to 32 percent)
Open-Eye Visuals	14.8% (95% interval 6 to 32 percent)

Subjective Effect Ontology

Experience Reports

Structured effect tags extracted from 144 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.

Visual

visual distortions 107 74.3%

1 unique effects extracted · Derived from Erowid & Bluelight reports

Dose–Effect Mapping

Experience Reports

How reported effects shift across dose tiers, based on 88 single-substance experience reports. The shaded band on each bar is its 95% interval. An arrow (↑ ↓) marks a change between the lowest and highest tier that count an effect only when the gap is bigger than chance would explain; ~ means no clear change. How changes are called

Limited tier coverage — most reports fall within the Heavy range. Effects at other dose levels may not be represented.

Oral dose range: 5.0–10.0 mg (median 6.0 mg)

Effect	Heavy (n=27)	Change with dose
visual distortions	89% (95% interval 72 to 96 percent)
nausea	74% (95% interval 55 to 87 percent)
anxiety	63% (95% interval 44 to 78 percent)
color enhancement	48% (95% interval 31 to 66 percent)
stimulation	41% (95% interval 24 to 59 percent)
confusion	37% (95% interval 22 to 56 percent)
auditory effects	37% (95% interval 22 to 56 percent)
music enhancement	30% (95% interval 16 to 48 percent)
sedation	26% (95% interval 13 to 45 percent)
empathy	22% (95% interval 11 to 41 percent)
euphoria	22% (95% interval 11 to 41 percent)
pupil dilation	18% (95% interval 8 to 37 percent)
hospital	18% (95% interval 8 to 37 percent)
closed-eye visuals	15% (95% interval 6 to 32 percent)
open-eye visuals	15% (95% interval 6 to 32 percent)
ego dissolution	15% (95% interval 6 to 32 percent)
motor impairment	11% (95% interval 4 to 28 percent)
headache	11% (95% interval 4 to 28 percent)
introspection	11% (95% interval 4 to 28 percent)
muscle tension	11% (95% interval 4 to 28 percent)

Showing top 20 of 27 effects

Dosage Distribution

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

Oral

Median: 6.0 mg IQR: 5.0–10.0 mg n=70

1 report gave a dose above the typical range (50 mg), so it is not in the figures above. It mentions hospital, emergency services or an overdose. Listing a dose here does not mean it is safe.

Show the report

50 mg · mentions hospital, emergency services or an overdose

Insufflated

Median: 6.0 mg IQR: 4.0–15.0 mg n=13

1 report gave a dose above the typical range (100 mg), so it is not in the figures above. It mentions hospital, emergency services or an overdose. Listing a dose here does not mean it is safe.

Show the report

100 mg · mentions hospital, emergency services or an overdose

Real-World Dose Distribution

Erowid

From 144 of 159 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Insufflated (n=21)

Median: 6.0mg 25th: 3.0mg 75th: 20.0mg 90th: 20.0mg

Oral (n=118)

Median: 6.0mg 25th: 5.0mg 75th: 11.5mg 90th: 17.15mg

Common Combinations

Most co-occurring substances, as a share of all 136 reports filed under 5-MeO-AMT; whiskers are 95% intervals

Form / Preparation

Most common forms and preparations, as a share of the 106 reports that give one; whiskers are 95% intervals

Body-Weight Dosing

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Oral

Median: 0.083 mg/kg IQR: 0.06–0.138 mg/kg n=65

1 report gave a dose above the typical range (0.847 mg/kg), so it is not in the figures above. It mentions hospital, emergency services or an overdose. Listing a dose here does not mean it is safe.

Show the report

0.847 mg/kg · mentions hospital, emergency services or an overdose

Insufflated

Median: 0.122 mg/kg IQR: 0.057–0.246 mg/kg n=12

1 report gave a dose above the typical range (1.471 mg/kg), so it is not in the figures above. It mentions hospital, emergency services or an overdose. Listing a dose here does not mean it is safe.

Show the report

1.471 mg/kg · mentions hospital, emergency services or an overdose

Redose Patterns

Redosing behavior across 109 reports

19.3% Redosed

1.3 Avg Doses

120m Median Interval

Read full reports on Erowid →

Harm Reduction

drugs.wiki

• Dose sensitivity is extreme at the milligram level; 5–8 mg oral has been associated with medical emergencies in community reports. Use a calibrated 0.001 g (milligram) scale and avoid volumetric errors. • Onset can be delayed to 90–120 minutes orally; redosing during the come-up is a common error that can produce protracted, dysphoric overstimulation and medical crises. • Insufflation is overrepresented in problem reports and can cause severe local irritation and systemic side effects; if used at all, doses must be markedly reduced compared with oral. • Material has been mis-sold as LSD or confused with AMT; paper blotter or drops have historically contained 5‑MeO‑AMT. Always reagent-test and, where available, use laboratory drug checking before ingestion. • Sympathomimetic effects (tachycardia, mydriasis, sweating, tremor, hypertension) are common; those with cardiovascular disease, seizure history, or uncontrolled hypertension should avoid. • Avoid combinations with MAOIs, MDMA, DXM, and serotonergic antidepressant stacks due to serotonin toxicity/hyperthermia risks; several severe intoxications and at least one death have been linked to high/unknown-dose 5‑MeO‑AMT, sometimes initially misattributed to LSD. • Plan for a very long tail of stimulation and potential insomnia; do not drive or operate machinery until fully baseline (commonly the day after, or longer at higher doses). • If severe agitation, hyperthermia, chest pain, confusion, or seizures occur, seek emergency care promptly; do not attempt to self-treat with additional substances. • Repeated administration over days shows rapid tolerance in animals; practical cross-tolerance with classic psychedelics is likely—space sessions by at least 10–14 days. • Because human pharmacokinetics are uncharacterized, start low, avoid stacked doses, and ensure a trusted sober sitter and a cool environment with hydration. • Where possible, use professional drug checking services to confirm identity/purity; field reagents (Ehrlich/Hofmann) can help rule in indoles and rule out NBOMes on blotter but are not definitive. • Avoid mixing with heavy exercise, hot environments, or dehydration, which can increase hyperthermia risk. • Store securely and label clearly to prevent confusion with AMT or other tryptamines.

References

Cited references

← Back to 5-MeO-AMT